NASDAQ:ATOSAtossa Genetics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Atossa Genetics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $3.97 +0.14 (+3.66 %) (As of 08/10/2020 04:00 PM ET) Add Compare Share Today's Range$3.76Now: $3.97▼$3.9950-Day Range$3.18MA: $3.83▼$4.3552-Week Range$0.75Now: $3.97▼$5.08Volume712,863 shsAverage Volume651,891 shsMarket Capitalization$36.56 millionP/E RatioN/ADividend YieldN/ABeta2.57 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Atossa Genetics Inc. a clinical-stage pharmaceutical company, focuses on the development and sale of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions in the United States. The company is conducting a Phase 2 clinical study using microcatheters to deliver fulvestrant as a potential treatment of ductal carcinoma in situ and breast cancer; and a pharmaceutical program under development is Endoxifen, an active metabolite of tamoxifen, as well as treatment for breast density and other breast health conditions. It offers ForeCYTE Breast Aspirator and FullCYTE Breast Aspirator, which collects specimens of nipple aspirate fluid (NAF)for cytological testing at a laboratory; and a transport kit to assist with the packaging and transport of NAF samples to a laboratory, as well as manufactures and sells various medical devices primarily consisting of tools to assist breast surgeons. Atossa Genetics Inc. was founded in 2009 and is headquartered in Seattle, Washington.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingAtossa Genetics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $8.00, Atossa Genetics has a potential upside of 101.5% from its current price of $3.97.Amount of Analyst CoverageAtossa Genetics has only been the subject of 1 research reports in the past 90 days. Previous Next 2.4 Community Rank Outperform VotesAtossa Genetics has received 202 “outperform” votes. (Add your “outperform” vote.)Underperform VotesAtossa Genetics has received 217 “underperform” votes. (Add your “underperform” vote.)Community SentimentAtossa Genetics has received 51.79% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Atossa Genetics and other stocks. Vote “Outperform” if you believe ATOS will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ATOS will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldAtossa Genetics does not currently pay a dividend.Dividend GrowthAtossa Genetics does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Atossa Genetics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 33.21% of the stock of Atossa Genetics is held by insiders.Percentage Held by InstitutionsOnly 2.46% of the stock of Atossa Genetics is held by institutions. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Atossa Genetics is -2.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Atossa Genetics is -2.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAtossa Genetics has a P/B Ratio of 2.90. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.18 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ATOS Previous Symbol CUSIPN/A CIK1488039 Webwww.atossagenetics.com Phone206-325-6086Debt Debt-to-Equity RatioN/A Current Ratio12.85 Quick Ratio12.85Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.37 per share Price / Book2.90Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-17,240,000.00 Net MarginsN/A Return on Equity-119.51% Return on Assets-104.79%Miscellaneous Employees4 Outstanding Shares9,208,000Market Cap$36.56 million Next Earnings Date8/11/2020 (Estimated) OptionableNot Optionable $3.97 +0.14 (+3.66 %) (As of 08/10/2020 04:00 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive ATOS News and Ratings via Email Sign-up to receive the latest news and ratings for ATOS and its competitors with MarketBeat's FREE daily newsletter. Atossa Genetics (NASDAQ:ATOS) Frequently Asked Questions How has Atossa Genetics' stock been impacted by COVID-19 (Coronavirus)? Atossa Genetics' stock was trading at $0.88 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ATOS shares have increased by 351.1% and is now trading at $3.97. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Atossa Genetics? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Atossa Genetics in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Atossa Genetics. When is Atossa Genetics' next earnings date? Atossa Genetics is scheduled to release its next quarterly earnings announcement on Tuesday, August 11th 2020. View our earnings forecast for Atossa Genetics. How were Atossa Genetics' earnings last quarter? Atossa Genetics Inc (NASDAQ:ATOS) announced its quarterly earnings results on Wednesday, May, 13th. The company reported ($0.32) EPS for the quarter, beating analysts' consensus estimates of ($0.39) by $0.07. View Atossa Genetics' earnings history. When did Atossa Genetics' stock split? How did Atossa Genetics' stock split work? Atossa Genetics shares reverse split on the morning of Friday, April 20th 2018. The 1-12 reverse split was announced on Friday, April 20th 2018. The number of shares owned by shareholders was adjusted after the market closes on Thursday, April 19th 2018. An investor that had 100 shares of Atossa Genetics stock prior to the reverse split would have 8 shares after the split. What price target have analysts set for ATOS? 1 equities research analysts have issued 12-month price targets for Atossa Genetics' stock. Their forecasts range from $8.00 to $8.00. On average, they expect Atossa Genetics' share price to reach $8.00 in the next twelve months. This suggests a possible upside of 101.5% from the stock's current price. View analysts' price targets for Atossa Genetics. Has Atossa Genetics been receiving favorable news coverage? News articles about ATOS stock have been trending somewhat negative on Monday, according to InfoTrie Sentiment Analysis. The research group scores the sentiment of media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Atossa Genetics earned a media sentiment score of -1.9 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the near term. View the latest news about Atossa Genetics. Who are some of Atossa Genetics' key competitors? Some companies that are related to Atossa Genetics include Restoration Robotics (HAIR), Soliton (SOLY), Venus Concept (VERO), PAVmed (PAVM), BeyondAirInc . (XAIR), Spectral Medical (EDTXF), Pro-Dex (PDEX), Neuronetics (STIM), SANUWAVE Health (SNWV), Nephros (NEPH), BRAINSWAY LTD/S (BWAY), Titan Medical (TMDI), Nephros (NEPHD), DarioHealth (DRIO) and AIT Therapeutics (AITB). View all competitors. What other stocks do shareholders of Atossa Genetics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Atossa Genetics investors own include AVEO Pharmaceuticals (AVEO), Alibaba Group (BABA), Biopharmx (BPMX), Amarin (AMRN), Protalix Biotherapeutics (PLX), Agile Therapeutics (AGRX), vTv Therapeutics (VTVT), Vaxart (VXRT), Biocept (BIOC) and Gevo (GEVO). Who are Atossa Genetics' key executives? Atossa Genetics' management team includes the following people: Dr. Steven C. Quay, Chairman, CEO & Pres (Age 68)Mr. Kyle Guse CPA, Esq., CPA, CFO, Gen. Counsel & Sec. (Age 55)Ms. Janet Rose Rea, Sr. VP of Regulatory, Quality & Clinical AffairsDr. Jack Cuzick, Member of Scientific Advisory Board What is Atossa Genetics' stock symbol? Atossa Genetics trades on the NASDAQ under the ticker symbol "ATOS." How do I buy shares of Atossa Genetics? Shares of ATOS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Atossa Genetics' stock price today? One share of ATOS stock can currently be purchased for approximately $3.97. How big of a company is Atossa Genetics? Atossa Genetics has a market capitalization of $36.56 million. Atossa Genetics employs 4 workers across the globe. What is Atossa Genetics' official website? The official website for Atossa Genetics is www.atossagenetics.com. How can I contact Atossa Genetics? Atossa Genetics' mailing address is 107 SPRING STREET, SEATTLE WA, 98104. The company can be reached via phone at 206-325-6086 or via email at [email protected] This page was last updated on 8/10/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
